Vendor Intelligence Report: Pura Peptides

Published 13 Jun 2026. 22-page investigative report on who is behind Pura Peptides: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Pura Peptides is a product-specific story, not a blanket quality call. Across 10 Finnrick lab tests, Pura records 8 pass / 2 fail, for an overall pass rate of 80%. Tirzepatide is the cleaner tested line; Retatrutide is the concern, with an identity failure and another failed result. The full report shows how that split changes under stricter Finnrick scoring views.

The records behind the storefront are uneven. Public profiles tie Pura to Excel Global, a Wyoming agent-service trail, and a principal name that also appears in the Xcel Research LLC record. A paid January 2026 press release claims operation since 2015, while RDAP and Wayback evidence show a parked-domain period and a 2024 active-storefront timeline.

The regulatory issue is related-entity rather than direct. FDA did not issue a warning letter to Pura in the materials reviewed; it did issue one to Xcel Research LLC, which overlaps with Pura by principal, address pattern, catalog class, and gated WordPress-style architecture. That linkage sits beside unavailable public COA verification, full-site login gating, Trustpilot removal, and a GLP-1 Forum shill warning.

For buyers, the practical read is directional: Pura’s Tirzepatide may be a more defensible candidate if the exact lot is independently verified; Pura’s Retatrutide is where testing dispersion and vendor opacity converge. The paywalled report resolves the underlying names, dates, screenshots, filings, and charts.

Inside the full report:

  • Appendix A Finnrick Laboratory Data, with per-product pass/fail detail and methodology-divergence charts for both tested products
  • Entity map connecting Excel Global/Pura, Xcel Research LLC, Andrew Pierce and Company Sage Agents LLC
  • Domain-history timeline using RDAP and Wayback captures from parked domain to WooCommerce storefront
  • Full FDA Warning Letter MARCS-CMS 694608 transcription and Pura/Xcel overlap analysis
  • Review-integrity evidence: Trustpilot removal, GLP-1 Forum shill warning, and coupon/promotion scan
  • Site-gating, COA-access, infrastructure, and Brazil-operator signal analysis

Risk assessment

  • Retatrutide identity and batch-reliability risk — high: Finnrick tested Retatrutide 8 times: 6 pass / 2 fail, rating 77.84%; field notes identify one failure as an identity failure.
  • Related-entity FDA enforcement risk — high: Xcel Research LLC, linked by Andrew Pierce, Wyoming address and overlapping catalog, received FDA Warning Letter MARCS-CMS 694608 for unapproved drug sales involving the same peptide classes.
  • Opaque ownership and traceability risk — high: Excel Global/Pura records route through mail/agent addresses and Andrew Pierce/Company Sage; beneficial owner and true operating location were not verified.
  • Misleading history and spokesperson risk — high: A January 2026 press release claims operation since 2015; RDAP/Wayback support a 2024 storefront and no verified Christopher Sinclair record surfaced.
  • Review-manipulation risk — high: Trustpilot profile removal and a GLP-1 Forum moderator warning that Pura used shill tactics make community praise unreliable.
  • Site-access, COA and official-channel verification risk — medium: The login wall blocks About/product/policy/COA material and no accessible authorized-channel list was found, raising pre-purchase and brand-confusion risk.